期刊文献+

培哚普利联合氟伐他汀对血清脂蛋白(a)的影响 被引量:1

Effects of combined use of perindopril and fluvastatin sodium on lipoprotein(a)
下载PDF
导出
摘要 目的观察培哚普利联合氟伐他汀对血清脂蛋白(a)[Lp(a)]浓度的影响。方法采用酶联免疫双抗体夹心法(ELISA)分别检测52例单独服用氟伐他汀(40 mg/d)及67例联合服用培哚普利(4 mg/d)和氟伐他汀(40 mg/d)患者前后血清(Lp(a)浓度的变化。结果单独服用氟伐他汀患者的Lp(a)浓度较前下降,而联合服用培哚普利及氟伐他汀患者的Lp(a)浓度较前下降更明显。结论联合服用培哚普利和氟伐他汀能更明显降低血清Lp(a)的浓度。 Objective To study the effects of combined use of perindopfil and fluvastatin sodium on serum concentration of lipoprotein(a). Methods Lp(a) in serum was determined by ELISA in 52 patients who took fluvastatin sodium only and 67 patients who took both fluvastatin sodium and perindopril. Results There was a little decrease of the concentration of Lp (a) in the patients who took fluvastatin sodium only. And there was a significient decrease of the concentration of Lp( a) in the patients who took both fluvastatin sodium and perindopril. Conclusion Combined therapy of fluvastatin sodium and perindopril could efficiently decrease serum concentration of Lp( a).
出处 《滨州医学院学报》 2006年第2期86-87,共2页 Journal of Binzhou Medical University
关键词 培哚普利 氟伐他汀 血清脂蛋白(a) perindopril, fluvastatin, lipoprotein ( a )
  • 相关文献

参考文献8

  • 1Jenkins A J, Best JD. The role of lipoprotein (a) in the vascular complications of diabetes mellitus [ J ]. Intern Med, 1995,237 (4) :359
  • 2Inagawa T. Diurnal and seasonal variations in the onset of primary intracerebral hemorrhage in individuals living in lzumo City ,Japan[ J]. J Neurosurg,2003,98 ( 2 ) : 326
  • 3Degaute JP, Borne P, Linkowski P, et al. Quantitative analysis of the 24-hour blood pressure and heart rate patterns in young men [ J ]. Hypertension, 1991,18 ( 2 ) : 199
  • 4Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein ( a ) as a risk factor for atherosclerosis and thrombosis:mechanistic insights from animal models[J]. Clin Biochem,2004,37(5 ) :333
  • 5刘茂东,李英,迟雁青,林海英,王保兴,顾连方.氟伐他汀治疗糖尿病肾病高脂蛋白(a)血症的疗效分析[J].中国实用内科杂志,2004,24(10):616-617. 被引量:1
  • 6Gotto AM Jr. The new cholesterol education imperative and some comments on niacin[J]. Am J Cardiol,1998,81 (4) :492
  • 7Boemi M, Sirolla C, Fumelli P, et al, Renal disease as a determinant of increased lipoprotein(a) concentrations in diabetic patients[ J ], Diabetes Care, 1999,22 ( 12 ) :2033
  • 8冼苏,廖蕴华,罗佐杰,郭宜,张红,陈宇明,邓有辉,凌影豫.2型糖尿病合并高血压与血管紧张素转化酶I基因多态性的相关性及其脂质代谢的研究[J].广西医科大学学报,2002,19(4):459-461. 被引量:7

二级参考文献8

共引文献6

同被引文献11

  • 1血脂康调整血脂对冠心病二级预防研究协作组.中国冠心病二级预防研究[J].中华心血管病杂志,2005,33(2):109-115. 被引量:222
  • 2李刚,周兴文.新的冠心病危险因素[J].心血管病学进展,2005,26(3):266-271. 被引量:24
  • 3Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the National Heart Lung and Blood Institute workshop on Lipoprotein(a) and cardiovascular disease: recent advances and future directions[ J]. Clin Chem, 2003, 47:1785 - 1796.
  • 4Yazici M, Dernirean S, Duma K, et al. Lipoprotein(a) levels in patients with unstable angina and their relationship with atherothrombosis and myocardial damage[J]. Int J Clin Pract, 2005,59(2):150- 155.
  • 5Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis mechanistic insights titan animal models [J]. Clin Biochem, 2004,37:333 - 343.
  • 6Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids LP(a) lipoprotein, and coronary artery disease[ J]. N Eng J Med, 2005,353 (1) : 46 - 57.
  • 7Jurukovska NM, Arsova V, Levchanska J, et al. Effects of statins(atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease[J]. Prilozi, 2007,28(2) : 137 - 148.
  • 8Solfrizzi v, Capurso C, Colacicco AM, et al. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering Lipoprotein(a) serum levels in patients with type-2 diabetes mellitus[J]. Atheroscleresis, 2006,188(2) :455 - 461.
  • 9Akaike M, Azuma H, Kagawa A, et al. Effects of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases[J]. Clin Chem, 2002,48:1454- 1459.
  • 10Schuster H. The GALAXY program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducin cardiovascular risk [ J ]. Expert Rev Cardiovasc Ther, 2007,5(2) : 177 - 193.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部